Masaru Obokata1, Yogesh N V Reddy1, Sorin V Pislaru1, Vojtech Melenovsky1, Barry A Borlaug2. 1. From Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (M.O., Y.N.V.R., S.V.P., V.M., B.A.B.); and Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic (V.M.). 2. From Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (M.O., Y.N.V.R., S.V.P., V.M., B.A.B.); and Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic (V.M.). borlaug.barry@mayo.edu.
Abstract
BACKGROUND: Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome. Phenotyping patients into pathophysiologically homogeneous groups may enable better targeting of treatment. Obesity is common in HFpEF and has many cardiovascular effects, suggesting that it may be a viable candidate for phenotyping. We compared cardiovascular structure, function, and reserve capacity in subjects with obese HFpEF, those with nonobese HFpEF, and control subjects. METHODS: Subjects with obese HFpEF (body mass index ≥35 kg/m2; n=99), nonobese HFpEF (body mass index <30 kg/m2; n=96), and nonobese control subjects free of HF (n=71) underwent detailed clinical assessment, echocardiography, and invasive hemodynamic exercise testing. RESULTS: Compared with both subjects with nonobese HFpEF and control subjects, subjects with obese HFpEF displayed increased plasma volume (3907 mL [3563-4333 mL] versus 2772 mL [2555-3133 mL], and 2680 mL [2380-3006 mL]; P<0.0001), more concentric left ventricular remodeling, greater right ventricular dilatation (base, 34±7 versus 31±6 and 30±6 mm, P=0.0005; length, 66±7 versus 61±7 and 61±7 mm, P<0.0001), more right ventricular dysfunction, increased epicardial fat thickness (10±2 versus 7±2 and 6±2 mm; P<0.0001), and greater total epicardial heart volume (945 mL [831-1105 mL] versus 797 mL [643-979 mL] and 632 mL [517-768 mL]; P<0.0001), despite lower N-terminal pro-B-type natriuretic peptide levels. Pulmonary capillary wedge pressure was correlated with body mass and plasma volume in obese HFpEF (r=0.22 and 0.27, both P<0.05) but not in nonobese HFpEF (P≥0.3). The increase in heart volumes in obese HFpEF was associated with greater pericardial restraint and heightened ventricular interdependence, reflected by increased ratio of right- to left-sided heart filling pressures (0.64±0.17 versus 0.56±0.19 and 0.53±0.20; P=0.0004), higher pulmonary venous pressure relative to left ventricular transmural pressure, and greater left ventricular eccentricity index (1.10±0.19 versus 0.99±0.06 and 0.97±0.12; P<0.0001). Interdependence was enhanced as pulmonary artery pressure load increased (P for interaction <0.05). Compared with those with nonobese HFpEF and control subjects, obese patients with HFpEF displayed worse exercise capacity (peak oxygen consumption, 7.7±2.3 versus 10.0±3.4 and12.9±4.0 mL/min·kg; P<0.0001), higher biventricular filling pressures with exercise, and depressed pulmonary artery vasodilator reserve. CONCLUSIONS: Obesity-related HFpEF is a genuine form of cardiac failure and a clinically relevant phenotype that may require specific treatments.
BACKGROUND:Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome. Phenotyping patients into pathophysiologically homogeneous groups may enable better targeting of treatment. Obesity is common in HFpEF and has many cardiovascular effects, suggesting that it may be a viable candidate for phenotyping. We compared cardiovascular structure, function, and reserve capacity in subjects with obese HFpEF, those with nonobese HFpEF, and control subjects. METHODS: Subjects with obese HFpEF (body mass index ≥35 kg/m2; n=99), nonobese HFpEF (body mass index <30 kg/m2; n=96), and nonobese control subjects free of HF (n=71) underwent detailed clinical assessment, echocardiography, and invasive hemodynamic exercise testing. RESULTS: Compared with both subjects with nonobese HFpEF and control subjects, subjects with obese HFpEF displayed increased plasma volume (3907 mL [3563-4333 mL] versus 2772 mL [2555-3133 mL], and 2680 mL [2380-3006 mL]; P<0.0001), more concentric left ventricular remodeling, greater right ventricular dilatation (base, 34±7 versus 31±6 and 30±6 mm, P=0.0005; length, 66±7 versus 61±7 and 61±7 mm, P<0.0001), more right ventricular dysfunction, increased epicardial fat thickness (10±2 versus 7±2 and 6±2 mm; P<0.0001), and greater total epicardial heart volume (945 mL [831-1105 mL] versus 797 mL [643-979 mL] and 632 mL [517-768 mL]; P<0.0001), despite lower N-terminal pro-B-type natriuretic peptide levels. Pulmonary capillary wedge pressure was correlated with body mass and plasma volume in obese HFpEF (r=0.22 and 0.27, both P<0.05) but not in nonobese HFpEF (P≥0.3). The increase in heart volumes in obese HFpEF was associated with greater pericardial restraint and heightened ventricular interdependence, reflected by increased ratio of right- to left-sided heart filling pressures (0.64±0.17 versus 0.56±0.19 and 0.53±0.20; P=0.0004), higher pulmonary venous pressure relative to left ventricular transmural pressure, and greater left ventricular eccentricity index (1.10±0.19 versus 0.99±0.06 and 0.97±0.12; P<0.0001). Interdependence was enhanced as pulmonary artery pressure load increased (P for interaction <0.05). Compared with those with nonobese HFpEF and control subjects, obesepatients with HFpEF displayed worse exercise capacity (peak oxygen consumption, 7.7±2.3 versus 10.0±3.4 and12.9±4.0 mL/min·kg; P<0.0001), higher biventricular filling pressures with exercise, and depressed pulmonary artery vasodilator reserve. CONCLUSIONS:Obesity-related HFpEF is a genuine form of cardiac failure and a clinically relevant phenotype that may require specific treatments.
Authors: J A Lima; P A Guzman; F C Yin; R K Brawley; L Humphrey; T A Traill; S D Lima; P Marino; M L Weisfeldt; J L Weiss Journal: Circulation Date: 1986-09 Impact factor: 29.690
Authors: Peter Wohlfahrt; Margaret M Redfield; Francisco Lopez-Jimenez; Vojtech Melenovsky; Garvan C Kane; Richard J Rodeheffer; Barry A Borlaug Journal: JACC Heart Fail Date: 2014-09-03 Impact factor: 12.035
Authors: Carl J Lavie; Martin A Alpert; Ross Arena; Mandeep R Mehra; Richard V Milani; Hector O Ventura Journal: JACC Heart Fail Date: 2013-04-01 Impact factor: 12.035
Authors: Chiadi E Ndumele; Kunihiro Matsushita; Mariana Lazo; Natalie Bello; Roger S Blumenthal; Gary Gerstenblith; Vijay Nambi; Christie M Ballantyne; Scott D Solomon; Elizabeth Selvin; Aaron R Folsom; Josef Coresh Journal: J Am Heart Assoc Date: 2016-07-28 Impact factor: 5.501
Authors: Barry A Borlaug; Kevin J Anstrom; Gregory D Lewis; Sanjiv J Shah; James A Levine; Gabe A Koepp; Michael M Givertz; G Michael Felker; Martin M LeWinter; Douglas L Mann; Kenneth B Margulies; Andrew L Smith; W H Wilson Tang; David J Whellan; Horng H Chen; Victor G Davila-Roman; Steven McNulty; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield Journal: JAMA Date: 2018-11-06 Impact factor: 56.272
Authors: Yogesh N V Reddy; Masaru Obokata; Jeffrey M Testani; G Michael Felker; W H Wilson Tang; Omar F Abou-Ezzeddine; Jie-Lena Sun; Hrishikesh Chakrabothy; Steven McNulty; Sanjiv J Shah; Gregory D Lewis; Lynne W Stevenson; Margaret M Redfield; Barry A Borlaug Journal: J Card Fail Date: 2019-10-13 Impact factor: 5.712
Authors: Yogesh N V Reddy; Rickey E Carter; Masaru Obokata; Margaret M Redfield; Barry A Borlaug Journal: Circulation Date: 2018-08-28 Impact factor: 29.690
Authors: Maximilian von Roeder; Johannes Tammo Kowallick; Karl-Philipp Rommel; Stephan Blazek; Christian Besler; Karl Fengler; Joachim Lotz; Gerd Hasenfuß; Christian Lücke; Matthias Gutberlet; Holger Thiele; Andreas Schuster; Philipp Lurz Journal: Clin Res Cardiol Date: 2019-05-03 Impact factor: 5.460